Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Lowered to Buy at StockNews.com

StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday. A number of other research analysts have also recently commented on ALNY. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, January 8th. […]

Related Keywords

Palo Alto ,Texas ,United States ,Ohio ,William Blair ,Piper Sandler ,Michaelw Bonney ,News Ratings For Alnylam Pharmaceuticals Daily ,Alnylam Pharmaceuticals Inc ,Goldman Sachs Group ,Alnylam Pharmaceuticals Stock Performance ,Eventide Asset Management ,Citigroup ,Alnylam Pharmaceuticals Company Profile ,Institutional Investors Weigh In On Alnylam Pharmaceuticals ,Nasdaq ,Square Quantitative Management ,Analyst Recommendations For Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals ,Wells Fargo Company ,Free Report ,Moderate Buy ,Get Free Report ,Director Michael ,Asset Management ,Employees Retirement System ,Retirement System ,Palo Alto Investors ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Downgrade ,Stocknews Com ,